Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea

Tai Hwan Park, Ji Sung Lee, Sang Soon Park, Youngchai Ko, Soo Joo Lee, Kyung Bok Lee, Jun Lee, Kyusik Kang, Jong Moo Park, Jay Chol Choi, Dong Eog Kim, Yong Jin Cho, Joon Tae Kim, Dae Hyun Kim, Jae Kwan Cha, Moon Ku Han, Juneyoung Lee, Mi Sun Oh, Kyung Ho Yu, Byung Chul LeeHee Joon Bae, Keun Sik Hong

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)

    Abstract

    Background The safety and efficacy of intravenous tissue plasminogen activator (IV-TPA) in the 3- to 4.5-hour window were largely driven from Western populations, but have not been systematically explored in Korean population. Methods We compared outcomes of acute ischemic stroke patients treated in the 3- to 4.5-hour window versus those in the 0- to 3-hour window, using a prospective multicenter registry database. Safety outcomes included symptomatic intracranial hemorrhage (SICH) and 3-month mortality and efficacy outcomes were the proportions of modified Rankin Scale (mRS) 0-1 and mRS 0-2 and the overall mRS distribution at 3 months. Results Among 723 patients consecutively treated with IV-TPA alone, 616 were treated within 3 hours and 107 treated between 3 and 4.5 hours. The median onset-to-treatment time was 115 minutes for 0- to 3-hour group and 217 minutes for 3- to 4.5-hour group. The SICH rate was higher in the 3- to 4.5-hour group than in the 0- to 3-hour group (4.7% vs. 3.1%), but the difference was not significant (adjusted odds ratio [OR] [95% confidence interval {CI}],.81 [.20-3.35]). There were no significant differences between the 3- to 4.5-hour and 0- to 3-hour groups in the 3-month mortality (19.6% vs. 12.0%), mRS 0-1 (39.3% vs. 42.9%), mRS 0-2 (48.6% vs. 55.7%), and the overall mRS distribution (adjusted proportional OR [95% CI],.94 [.63-1.41]) after adjusting for covariates. Conclusions IV-TPA treatment can be safely and efficaciously administered to eligible Korean patients up to the extended time window of 4.5 hours. However, efforts to expedite the treatment should not be neglected.

    Original languageEnglish
    Pages (from-to)1805-1812
    Number of pages8
    JournalJournal of Stroke and Cerebrovascular Diseases
    Volume23
    Issue number7
    DOIs
    Publication statusPublished - 2014 Aug

    Keywords

    • Intravenous recombinant tissue plasminogen activator
    • acute stroke
    • ischemic stroke
    • safety

    ASJC Scopus subject areas

    • Surgery
    • Rehabilitation
    • Clinical Neurology
    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea'. Together they form a unique fingerprint.

    Cite this